HRMY - Company ID 0001802665
Harmony Biosciences Holdings, Inc. trades as HRMY and has a market capitalization of $2.13 B, making it the #2078 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $868.45M, up 21.5% from the prior year and net income of $158.69M. This page tracks Harmony Biosciences Holdings, Inc. through 434 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years Harmony Biosciences Holdings, Inc.'s revenue grew from $6.00M to $868.45M, a compound annual growth rate of 129.2%. Net profit margin expanded from -2535.1% to 18.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| New insider ownership | 3 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
Harmony Biosciences to Participate in Upcoming Investor Conferences | Harmony Biosciences
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities | Harmony Biosciences
To participate in the call, please dial 888.596.4144 (domestic) or 646.968.2525 (international or alternate), and Conference ID 6626692. It is recommended that you dial in at least 10 minutes prior to the call.
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting | Harmony Biosciences
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer | Harmony Biosciences
The largest companies sharing Harmony Biosciences Holdings, Inc.'s SEC industry classification (pharmaceutical preparations).
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.13 B as of 2026-07-11, ranking #2078 among US-listed companies.
Harmony Biosciences Holdings, Inc. reported revenue of $868.45M for fiscal year 2025, an increase of 21.5% year over year.
Yes. Harmony Biosciences Holdings, Inc. reported net income of $158.69M in its latest fiscal year.